Combining bevacizumab and chemoradiation in rectal cancer. Translational results of the AXEBeam trial.

ABSTRACT: Objective: Insights about differences in tumor vasculature and how it reacts to VEGF inhibition is limited, but nevertheless of major relevance to anti-angiogenic therapy. In this study we therefore characterize the effect of bevacizumab combined with chemoradiotherapy (CRT), and explore molecular and genetic markers for response prediction to this combination treatment. Material and Methods: In an academic multicentric randomized phase II study, patients with advanced rectal cancer have been treated with bevacizumab (5mg/kg) in combination with capecitabine (1650mg/m2/day) and radiotherapy (45Gy; 1.8Gy/day) with (50mg/m2) or without oxaliplatin prior to surgery. Of 59 patients, tumor tissue and blood samples were collected before treatment and after the first loading dose of bevacizumab b

ORGANISM(S): Homo sapiens

SUBMITTER: Wouter Van Delm 

PROVIDER: E-GEOD-60331 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress